

**MARYLAND PRESCRIPTION DRUG AFFORDABILITY STAKEHOLDER COUNCIL  
VIRTUAL MEETING  
February 23, 2026  
Minutes**

**Agenda Item 1**

**Call to Order:**

Co-Chair Lorriane Diana called the meeting to order at 2:01 PM.

**(Roll Call) Stakeholder Council Members Present:**

Pallavi Arora, Angela Bryant, Lorraine Diana, Robert Embry, John Gambrill, Candace Hall, Sherita Golden, Jim Gutman, Deron Johnson, Erica Miller, Eric Morse, Marc Nicole, Shaun O'Brien, Mandi Poplawski, Amy Prentice, Monica Elise Proctor Wilson, Kimberly Robinson, Glenn Scheider, Kelly Schultz, Danita Tolson, Joseph Winn

**Agenda Item 2**

**December 15, 2026 Meeting Minutes**

Co-Chair Diana asked for a motion to approve the December 15, 2026 meeting minutes as submitted. Shaun O'Brien made the motion, which Jim Gutman seconded. The PDASC unanimously approved the minutes.

**Action: Minutes APPROVED**

**Agenda Item 3**

**Opportunity for Public Comment**

The PDASC received 3 written comments which were shared with the PDASC and posted to the website.

The following people provided oral public comment:

1. George Huntley, Diabetes Patient Advocacy Coalition, Agenda Item 4
2. Dr. Jonas Nguh, Maryland Public Health Association, Agenda Item 4

**Agenda Item 4**

**Update on Cost Review Study Process**

Executive Director Andrew York provided a short verbal update on the Cost Review Study process. Dr. York gave an update on the six drugs chosen for Cost Review Study and their current status in the process. The PDASC had the opportunity to discuss and ask questions on this agenda item.

**Agenda Item 5**

**Feedback from the Stakeholder Council on the Cost Review Study Process and Policy Review Process**

Dr. York gave a presentation to the PDASC about obtaining feedback from the Stakeholder Council on the Cost Review Study Process and Policy Review Process. The purpose of this agenda item is to gather input from the Stakeholder Council regarding the Cost Review Study process (COMAR 14.01.04.01, et seq.) and Policy Review Procedures (COMAR 14.01.05.01, et

seq.). Dr. York gave an overview of the current process for the Cost Review Study Process and Policy Review Process. The PDASC was provided with the current regulation on the Cost Review Study Process and Policy Review Process regulations prior to the meeting and were asked to come prepared to answer the following questions:

1. What parts of the regulations are effective?
2. What parts might be improved? How?

The PDASC had a robust discussion and provided feedback on the regulations. The main themes included: immediate relief solutions for high cost drugs, public engagement and accessibility, and regulatory and policy considerations. Staff will provide an update to the Board at an upcoming meeting including the PDASC feedback. This presentation is posted on the Stakeholder Council page of the website.

### **Agenda Item 6**

#### **Administrative Update**

- Spencer Dixon, Strategic Operations Specialist, was introduced. The PDAB is now fully staffed again.
- Christina Shaklee, Health Policy Analyst provided a short legislative update.

### **Agenda Item 7**

#### **Co-Chair's Update**

- The next regularly scheduled PDASC Meeting is on April 27, 2026. Staff is considering a hybrid meeting.

### **Agenda Item 8**

#### **Adjournment**

Co-Chair Nicole thanked everyone for attending the meeting and asked for a motion to adjourn the meeting. Shaun O'Brien made the motion which was seconded by Dr. Sherita Golden.

**Adjourned at 3:18 PM.**